Tau PET Scans in Alzheimer’s

Tau PET is becoming an important new window into Alzheimer’s disease. With the August 2026 FDA approval of Tauklarify, clinicians now have two FDA-approved tau PET tracers—Tauvid and Tauklarify. Unlike amyloid testing, which helps identify whether Alzheimer’s biology is present, tau PET can show where aggregated tau has accumulated and how extensively it has spread. This high-level guide explains what tau PET adds, how the two tracers differ, and why tau imaging may become increasingly important for understanding disease stage and progression.